Medicenna Therapeutics Corp. (MDNAF)
Market Closed
14 May, 20:00
NASDAQ NASDAQ Primary $
0. 75
-0.03
-4.1%
After Hours
$
-0.07 -9.21% 0. 68
10.93M Market Cap
- P/E Ratio
0% Div Yield
25,000 Volume
- Eps
$ 0.78
Previous Close Day Range
0.75 0.77
Year Range
0.6 2.2
Earnings results expected in 9 days
Summary
MDNAF closed Wednesday lower at $0.75, a decrease of 4.1% from Tuesday's close, completing a monthly increase of 9.82% or $0.07. Over the past 12 months, MDNAF stock lost -34.3%.
MDNAF is not paying dividends to its shareholders.
The last earnings report, released on Feb 12, 2025, missed the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Jun 25, 2025.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (USD).
Want to track MDNAF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
MDNAF Chart
Loading, please wait...
Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
- Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck's (known as MSD outside of Canada and the US) KEYTRUDA® (pembrolizumab) in ongoing Phase 1/2 ABILITY-1 trial including one complete response, one partial response and five stable disease (as reported on Dec. 5, 2024)
Globenewswire | 4 months ago
Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update
MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression after one or more immune checkpoint inhibitor (ICI) therapy
Globenewswire | 7 months ago
Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference
MDNA209 is a first-in-class “beta-enhanced” IL-2 Super-antagonist being developed for the potential treatment of autoimmune diseases, a disorder attributed to an imbalance of the immune system and affecting 5 to 10% of the global population
Globenewswire | 9 months ago
Medicenna Therapeutics Corp. Dividends
MDNAF is not paying dividends to its shareholders.
Medicenna Therapeutics Corp. Earnings
| 25 Jun 2025 (9 Days) Date | | - Cons. EPS | - EPS |
| 12 Feb 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 27 Sep 2024 Date | | - Cons. EPS | - EPS |
| 2 Aug 2024 Date | | - Cons. EPS | - EPS |
MDNAF is not paying dividends to its shareholders.
| 25 Jun 2025 (9 Days) Date | | - Cons. EPS | - EPS |
| 12 Feb 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 27 Sep 2024 Date | | - Cons. EPS | - EPS |
| 2 Aug 2024 Date | | - Cons. EPS | - EPS |
Medicenna Therapeutics Corp. (MDNAF) FAQ
What is the stock price today?
The current price is $0.75.
On which exchange is it traded?
Medicenna Therapeutics Corp. is listed on NASDAQ.
What is its stock symbol?
The ticker symbol is MDNAF.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 10.93M.
What is the earnings per share?
The EPS is 0.
When is the next earnings date?
The next earnings report will release on Jun 25, 2025.
Has Medicenna Therapeutics Corp. ever had a stock split?
No, there has never been a stock split.
Medicenna Therapeutics Corp. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Fahar Merchant Ph.D. CEO | NASDAQ Exchange | CA58490H1073 ISIN |
| Canada Country | 16 Employees | - Last Dividend | - Last Split | - IPO Date |
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Contact Information
Address: 2 Bloor Street West
Phone: 416- 648-5555
Website: https://www.medicenna.com
2025 © Marketlog. All Rights Reserved.
